Hub and spoke IP strategies are generating billions of dollars in biopharma
New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.